269 related articles for article (PubMed ID: 37197624)
1. A narrative review from gut to lungs: non-small cell lung cancer and the gastrointestinal microbiome.
Shah H; Ng TL
Transl Lung Cancer Res; 2023 Apr; 12(4):909-926. PubMed ID: 37197624
[TBL] [Abstract][Full Text] [Related]
2. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
[TBL] [Abstract][Full Text] [Related]
3. The Gut Microbiome and Cancer Immunotherapy: Can We Use the Gut Microbiome as a Predictive Biomarker for Clinical Response in Cancer Immunotherapy?
Oh B; Boyle F; Pavlakis N; Clarke S; Eade T; Hruby G; Lamoury G; Carroll S; Morgia M; Kneebone A; Stevens M; Liu W; Corless B; Molloy M; Kong B; Libermann T; Rosenthal D; Back M
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638308
[No Abstract] [Full Text] [Related]
4. Lung microbiome: an emerging player in lung cancer pathogenesis and progression.
Karvela A; Veloudiou OZ; Karachaliou A; Kloukina T; Gomatou G; Kotteas E
Clin Transl Oncol; 2023 Aug; 25(8):2365-2372. PubMed ID: 36995519
[TBL] [Abstract][Full Text] [Related]
5. Gut microbiome and response to checkpoint inhibitors in non-small cell lung cancer-A review.
Nagasaka M; Sexton R; Alhasan R; Rahman S; Azmi AS; Sukari A
Crit Rev Oncol Hematol; 2020 Jan; 145():102841. PubMed ID: 31884204
[TBL] [Abstract][Full Text] [Related]
6. Chronological analysis of the gut microbiome for efficacy of atezolizumab-based immunotherapy in non-small cell lung cancer: Protocol for a multicenter prospective observational study.
Shoji F; Miura N; Tagawa T; Tsukamoto S; Okamoto T; Yamazaki K; Hamatake M; Takeo S
Thorac Cancer; 2022 Oct; 13(19):2829-2833. PubMed ID: 36063818
[TBL] [Abstract][Full Text] [Related]
7.
Tomita Y; Goto Y; Sakata S; Imamura K; Minemura A; Oka K; Hayashi A; Jodai T; Akaike K; Anai M; Hamada S; Iyama S; Saruwatari K; Saeki S; Takahashi M; Ikeda T; Sakagami T
Oncoimmunology; 2022; 11(1):2081010. PubMed ID: 35655708
[TBL] [Abstract][Full Text] [Related]
8. The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC.
Jin Y; Dong H; Xia L; Yang Y; Zhu Y; Shen Y; Zheng H; Yao C; Wang Y; Lu S
J Thorac Oncol; 2019 Aug; 14(8):1378-1389. PubMed ID: 31026576
[TBL] [Abstract][Full Text] [Related]
9. Immune Gene Expression Covaries with Gut Microbiome Composition in Stickleback.
Fuess LE; den Haan S; Ling F; Weber JN; Steinel NC; Bolnick DI
mBio; 2021 May; 12(3):. PubMed ID: 33947750
[TBL] [Abstract][Full Text] [Related]
10. Broad-spectrum antibiotics associated gut microbiome disturbance impairs T cell immunity and promotes lung cancer metastasis: a retrospective study.
Xu K; Cai J; Xing J; Li X; Wu B; Zhu Z; Zhang Z
BMC Cancer; 2022 Nov; 22(1):1182. PubMed ID: 36384523
[TBL] [Abstract][Full Text] [Related]
11. Advances in research on the relationship between the gut microbiome and cancer.
Song P; Wang QB; Liang B; Jiang SJ
Eur Rev Med Pharmacol Sci; 2021 Aug; 25(16):5104-5112. PubMed ID: 34486684
[TBL] [Abstract][Full Text] [Related]
12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
13. Relating Gut Microbiome and Its Modulating Factors to Immunotherapy in Solid Tumors: A Systematic Review.
Huang C; Li M; Liu B; Zhu H; Dai Q; Fan X; Mehta K; Huang C; Neupane P; Wang F; Sun W; Umar S; Zhong C; Zhang J
Front Oncol; 2021; 11():642110. PubMed ID: 33816289
[No Abstract] [Full Text] [Related]
14. Onco-biome in pharmacotherapy for lung cancer: a narrative review.
Tateishi AT; Okuma Y
Transl Lung Cancer Res; 2022 Nov; 11(11):2332-2345. PubMed ID: 36519027
[TBL] [Abstract][Full Text] [Related]
15. Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies.
Lu Y; Yuan X; Wang M; He Z; Li H; Wang J; Li Q
J Hematol Oncol; 2022 Apr; 15(1):47. PubMed ID: 35488243
[TBL] [Abstract][Full Text] [Related]
16. Exploring the role of gut microbiome in male reproduction.
Wang Y; Xie Z
Andrology; 2022 Mar; 10(3):441-450. PubMed ID: 34918486
[TBL] [Abstract][Full Text] [Related]
17. Gut microbiome and cancer immunotherapy.
Li W; Deng Y; Chu Q; Zhang P
Cancer Lett; 2019 Apr; 447():41-47. PubMed ID: 30684593
[TBL] [Abstract][Full Text] [Related]
18. Do Antibiotics Cause Obesity Through Long-term Alterations in the Gut Microbiome? A Review of Current Evidence.
Vallianou N; Dalamaga M; Stratigou T; Karampela I; Tsigalou C
Curr Obes Rep; 2021 Sep; 10(3):244-262. PubMed ID: 33945146
[TBL] [Abstract][Full Text] [Related]
19. Interaction between drugs and the gut microbiome.
Weersma RK; Zhernakova A; Fu J
Gut; 2020 Aug; 69(8):1510-1519. PubMed ID: 32409589
[TBL] [Abstract][Full Text] [Related]
20. The effects of proton pump inhibitors on the microbiome in young children.
Levy EI; Hoang DM; Vandenplas Y
Acta Paediatr; 2020 Aug; 109(8):1531-1538. PubMed ID: 32027402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
